Stockscreener 앱 받기
1.01
0.00%
0.00
시간 외 거래:
1.04
0.03
+2.97%
전일 마감가:
$1.01
열려 있는:
$1
하루 거래량:
1.54M
Relative Volume:
0.80
시가총액:
$116.51M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.6121
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+2.73%
1개월 성능:
-6.48%
6개월 성능:
-9.82%
1년 성능:
-45.99%
1일 변동 폭
$1.00
$1.06
1주일 범위
$0.97
$1.06
52주 변동 폭
$0.6611
$1.9399
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.01 | 116.51M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
ETF Watch: Can Fate Therapeutics Inc stock beat market expectations this quarterTrade Exit Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance
Is Fate Therapeutics Inc. stock positioned for long term growth2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда
Will Fate Therapeutics Inc. stock keep outperforming rivalsEarnings Trend Report & Safe Swing Trade Setups - Улправда
Why Fate Therapeutics Inc. stock could outperform in 2025Layoff News & Expert Curated Trade Ideas - DonanımHaber
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from NASDAQ Biotechnology Index - marketscreener.com
Why hedge funds are buying Fate Therapeutics Inc. stockJuly 2025 Spike Watch & Long-Term Growth Plans - Улправда
Fate Therapeutics Earnings Notes - Trefis
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Healthy Upside Potential: Fate Therapeutics Inc (FATE) - setenews.com
Fate Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Fast Profit Portfolio Plans - earlytimes.in
Fate Therapeutics reports positive lupus treatment data at ASH meeting - Investing.com
Fate Therapeutics reports positive lupus treatment data at ASH meeting By Investing.com - Investing.com Canada
Fate Therapeutics Reports Positive Clinical Updates for FT819 in Systemic Lupus Erythematosus and Introduces Next-Generation CAR T-Cell Programs at ASH Annual Meeting - Quiver Quantitative
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs - The Manila Times
Fate Therapeutics, Inc. Presents Updated Phase 1 Clinical Data of FT819 Off-The-Shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-The-Shelf Car T-Shelf CAR T-Cell Programs - marketscreener.com
Fate Therapeutics Presents Updated Phase 1 Clinical Data of - GlobeNewswire
Fate Therapeutics (NASDAQ:FATE) Stock Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
How Fate Therapeutics Inc. stock valuations compare to rivalsWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Why Fate Therapeutics Inc. stock remains on buy listsWatch List & Safe Entry Point Identification - Newser
Will Fate Therapeutics Inc. stock benefit from sector rotationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Published on: 2025-12-02 03:44:47 - Newser
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Check Out Fate Therapeutics Inc (FATE)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 - Quiver Quantitative
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation - simplywall.st
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts - TipRanks
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-16 18:05:52 - newser.com
Will Fate Therapeutics Inc. stock recover faster than market2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities - The Globe and Mail
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks - MSN
Why Fate Therapeutics Inc. stock remains a top recommendationPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):